A Phase III Study of MP-513 in Combination With Sulfonylurea in Japanese Patients With Type 2 Diabetes Mellitus.
Phase of Trial: Phase III
Latest Information Update: 20 Jun 2014
At a glance
- Drugs Teneligliptin (Primary) ; Sulfonylureas
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 10 Jun 2017 Biomarkers information updated
- 31 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Aug 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.